Rights and permissions
About this article
Cite this article
Tolvaptan: advantages over standard therapy in CHF. Inpharma Wkly. 1420, 7–8 (2004). https://doi.org/10.2165/00128413-200414200-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128413-200414200-00015